37 Breast Cancer Clinical Trials in Nashville, TX (2026)

Q: How do I join a clinical trial in Nashville?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Nashville research site will contact you.

Recruiting Breast Cancer Studies in Nashville

NCT00899301Recruiting

Collecting and Storing Tissue Samples From Women With or Without Breast Cancer

RATIONALE: Collecting and storing samples of tissue, blood, and urine from patients with or without breast cancer to study in the laboratory may help the study of cancer. PURPOSE: This research study...

Nashville, TX4,000 participantsVanderbilt-Ingram Cancer Center

View Study Details

NCT06188520Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade s...

Nashville, TX564 participantsAstraZeneca

View Study Details

NCT06797635Recruiting

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The ma...

Nashville, TX372 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06533826Recruiting

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan fol...

Nashville, TX357 participantsAna C Garrido-Castro, MD

View Study Details

NCT04606446Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a sin...

Nashville, TX320 participantsPfizer

View Study Details

NCT06726148Recruiting

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. ...

Nashville, TX280 participantsNovartis Pharmaceuticals

View Study Details

NCT05683418Recruiting

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

The goal of this clinical trial is to evaluate the safety and efficacy of TOS-358 in women with HR+ HER2- metastatic breast cancer whose tumors have a mutation in PIK3CA and who meet all other study e...

Nashville, TX241 participantsTotus Medicines

View Study Details

NCT07288359Recruiting

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical e...

Nashville, TX205 participantsNovartis Pharmaceuticals

View Study Details

NCT05898399Recruiting

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with Olaparib or Niraparib....

Nashville, TX181 participantsArtios Pharma Ltd

View Study Details

NCT06784193Recruiting

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltran...

Nashville, TX180 participantsOlema Pharmaceuticals, Inc.

View Study Details

NCT05872295Recruiting

IKS014 in Advanced Solid Tumors That Express HER2

This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targe...

Nashville, TX165 participantsIksuda Therapeutics Ltd.

View Study Details

NCT05770531Recruiting

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

This phase II trial tests how well evaluating circulating tumor deoxyribonucleic acid (ctDNA) works to guide therapy-change decisions in treating patients with triple-negative breast cancer (TNBC) tha...

Nashville, TX160 participantsVanderbilt-Ingram Cancer Center

View Study Details

NCT07647328Recruiting

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC who have not received any other systemic...

Nashville, TX150 participantsAstraZeneca

View Study Details

NCT05523947Recruiting

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastati...

Nashville, TX147 participantsYuhan Corporation

View Study Details

NCT06475937Recruiting

A Study of DM001 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM001 for patients with the advanced solid tumors. DM001 is an experimental drug which is not approved by...

Nashville, TX128 participantsXadcera Biopharmaceutical (Suzhou) Co., Ltd.

View Study Details

NCT06926920Recruiting

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNB...

Nashville, TX100 participantsGilead Sciences

View Study Details

NCT04841148Recruiting

Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer

This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor dissemin...

Nashville, TX96 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT05573126Recruiting

Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

The aim of this study is to identify the optimal dose for Vosilasarm (EP0062) as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, an...

Nashville, TX95 participantsEllipses Pharma

View Study Details

NCT05386108Recruiting

Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-pos...

Nashville, TX73 participantsStemline Therapeutics, Inc.

View Study Details

NCT05693766Recruiting

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone recept...

Nashville, TX64 participantsSonya Reid

View Study Details

NCT05187832Recruiting

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in...

Nashville, TX61 participantsKind Pharmaceuticals LLC

View Study Details

NCT05501704Recruiting

ETHAN - ET for Male BC

This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male...

Nashville, TX60 participantsJose Pablo Leone

View Study Details

NCT05422794Recruiting

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

This phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatm...

Nashville, TX57 participantsNational Cancer Institute (NCI)

View Study Details

NCT05455619Recruiting

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

This is a Phase 1b/2, open-label, parallel-arms pilot study in men and post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the ...

Nashville, TX52 participantsSynDevRx, Inc.

View Study Details

NCT07016399Recruiting

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

This phase II trial compares the effect of adding darolutamide to standard therapy versus standard therapy alone before surgery for the treatment of patients with stage II-IIIA androgen receptor posit...

Nashville, TX51 participantsVandana Abramson

View Study Details

NCT06827613Recruiting

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Comb...

Nashville, TX50 participantsMarengo Therapeutics, Inc.

View Study Details

NCT06075810Recruiting

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable....

Nashville, TX48 participantsMBQ Pharma

View Study Details

NCT04434040Recruiting

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulatin...

Nashville, TX40 participantsDana-Farber Cancer Institute

View Study Details

NCT05748834Recruiting

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals...

Nashville, TX36 participantsSCRI Development Innovations, LLC

View Study Details

NCT07524855Recruiting

A Study of HLD-0117 in Patients With Metastatic Breast Cancer

Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed...

Nashville, TX33 participantsHalda Therapeutics OpCo, Inc.

View Study Details

NCT07558733Recruiting

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other antican...

Nashville, TX32 participantsFaeth Therapeutics

View Study Details

NCT05029999Recruiting

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil...

Nashville, TX30 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT05919108Recruiting

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers. Neratinib is in a class of me...

Nashville, TX30 participantsVanderbilt-Ingram Cancer Center

View Study Details

NCT03990896Recruiting

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation....

Nashville, TX30 participantsMassachusetts General Hospital

View Study Details

NCT07192432Recruiting

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers....

Nashville, TX27 participantsVironexis Biotherapeutics Inc.

View Study Details

NCT07555210Recruiting

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells....

Nashville, TX25 participantsJessica Mezzanotte Sharpe

View Study Details

NCT07427394Recruiting

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast canc...

Nashville, TX24 participantsAstraZeneca

View Study Details

About Breast Cancer Clinical Trials in Nashville

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 37 breast cancer clinical trials recruiting participants in Nashville, TX. These studies are seeking a combined 8,564 participants. Research is being sponsored by Vanderbilt-Ingram Cancer Center, AstraZeneca, Merck Sharp & Dohme LLC and 29 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Nashville — FAQ

Are there breast cancer clinical trials in Nashville?

Yes, there are 37 breast cancer clinical trials currently recruiting in Nashville, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Nashville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Nashville research site will contact you about next steps.

Are clinical trials in Nashville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Nashville studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 37 active trials in Nashville are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated July 13, 2026 from ClinicalTrials.gov